Euroscreen Announces Its Clinical Advisory Board

Share Article

Worldwide renowned clinicians to guide ESN364 promising developments.

Euroscreen, a drug development company focused on the development of novel GPCR drug concepts announced its Clinical Advisory Board members as experts in therapy and disease management in the field of Women’s Health Disorders. Philippe Bouchard, M.D., Professor of Medicine, specialized in Endocrinology, Obstetrics and Gynecology from Pierre et Marie Curie University in Paris, France; Bart Fauser, M.D., Ph.D., Professor of Reproductive Medicine from University of Utrecht, The Netherlands; Richard Legro, M.D., Professor of Obstetrics and Gynecology at Penn State Clinical and Translational Institute, Pennsylvania, USA; and Hugh Taylor, M.D., Professor of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine, Connecticut, USA.

“We are proud to have assembled such a Board of world experts in Women’s Health. The insight and guidance provided by our Clinical Advisors is a major asset in promoting the successful development of our first-in-class drug candidate, ESN364,” said Jean Combalbert, CEO of Euroscreen. “ESN364 is on-schedule for initiation of Phase I studies in Q3, 2013and Phase II proof-of-concept studies are projected to begin in Q4, 2014”.

Philippe Bouchard, M.D.
is presently Professor of Medicine and the Head of Endocrinology and Director of EA 1533, Genetics of Human Reproduction at Hospital St Antoine, Paris, France. He is internationally known within the fields of Endocrinology, Reproduction, Diabetology, and Nutrition, and he is the Past President of the Société Française d'Endocrinologie (SFE). Prof. Bouchard serves the European Society of Gynecology (ESG) as their Honorary Chairman, and he is also a member and the Secretary of the Executive Committee of the European Society of Endocrinology (ESE). Since 1989 he has been a member of the International Committee for Contraception Research (ICCR); a network of scientists and clinical investigators who conduct clinical trials to test the safety, efficacy, and acceptability of Council-developed reproductive health products. In 2002 he was received as a doctor Honoris Causa by the University of Liège, Belgium. In 2008 he was elected as corresponding member of the National Academy of Medicine (2008).

Bart CJM Fauser, M.D., Ph.D.
is Professor of Reproductive Medicine, University of Utrecht, The Netherlands. Chair Division of Woman & Baby (Dpts Reproductive Medicine & Gynecology, Obstetrics, Neonatology), University Medical Center, Utrecht, (since 2004). Former Professor of Reproductive Endocrinology and director Center of Reproductive Medicine, Erasmus Medical Center, Rotterdam, The Netherlands (1996-2003); Visiting Professor, University Southampton, UK (since 2010), Saal van Zwanenberg Professor, Center of Reproductive Medicine, Free University, Brussels, Belgium (2003-2008); Visiting Professor, Stanford School of Medicine, Palo Alto, California, USA (1993-1995), and Fulbright post-doctoral Scholar, University of California, San Diego, California (1987-1988). Former Editor-in-Chief ‘Human Reproduction Update’ (2001-2007). His major research interest is the pathophysiology of human ovarian function. He serves on many international editorial boards, has been active in many international societies.

Richard S Legro, M.D.
is Professor of Obstetrics and Gynecology and Public Health Sciences and Co-Leader, Clinical Services Core (CSC) of the Penn State Clinical and Translational Institute. His research and clinical practice are primarily focused on polycystic ovary syndrome (PCOS), but he has extensive experience in infertility studies (male and female), leiomyomas, studies of reproductive maturation, and noncontraceptive indications for hormonal contraception, including the treatment of female hirsutism and dysmenorrhea. He has served as the lead principal investigator on many multicenter randomized controlled trials in these areas. He is an Associate Editor of Fertility and Sterility and Seminars of Reproductive Medicine and on the editorial board of Endocrine Reviews and Endocrinology. He has been active in many professional organizations in Endocrinology and Reproductive Medicine.

Hugh Taylor, M.D.
is the Anita O'Keeffe Young Professor and Chair, Department of Obstetrics Gynecology and Reproductive Sciences at Yale School of Medicine and Chief of Obstetrics and Gynecology at Yale-New Haven Hospital. He is also Professor of Molecular, Cellular and Developmental biology at Yale University. His clinical interests include IVF, infertility, endometriosis, implantation, menopause, uterine anomalies and DES exposure. He is a board certified specialist in Obstetrics and Gynecology and in Reproductive Endocrinology. His clinical research centers on implantation, endometriosis and menopause. His basic science research focuses on uterine development, the regulation of developmental gene expression by sex steroids, endocrine disruption, and on stem cells. He is the Editor-In-Chief of Reproductive Sciences.

About Euroscreen
Euroscreen has a drug development track-record with multiple innovative and proprietary chemical entities targeting G Protein Coupled Receptors (GPCR).

Euroscreen is advancing its orally-available and highly specific lead program ESN364 into clinical trials for women’s diseases such Endometriosis and Poly-Cystic Ovary Syndrome (PCOS). The Company is also actively seeking partners for other pharmaceutical candidates, such as its ESN282 program for the treatment of inflammatory diseases such as Ulcerative Colitis.

Euroscreen is a Belgium based, private Drug Discovery and Development company providing first-in-class small molecule drug candidates for therapeutic areas including inflammation, neurodegenerative diseases and women’s diseases. Euroscreen also has a dedicated business providing fee-for-service drug candidate testing (Euroscreen FAST) for biopharmaceutical companies worldwide.

The Company is backed by leading investors, including Vesalius Biocapital, SRIW, Fortis Private Equity, and others.

Further information about the Company and its drug development programs can be found online at or contacting info(at)euroscreen(dot)com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Euroscreen SA
(716) 308-6693
Email >
Visit website